Pharmaceutical products – based on relation from manufactured- to administrable dose form – NoMA’s solution to meet needs in clinical practice

Cathrine Bergøy, Thanh Kieu
NoMA (Norwegian Medicines Agency)

24.05.2023
Agenda

► Presentation of NoMA and the SAFEST project
► Pharmaceutical products and pharmaceutical dose forms
  ▶ Definitions
  ▶ Challenges
  ▶ Clinical use
► NoMAs solution to meet needs in clinical practice
► Other aspects for PhPID-generation to meet clinical practice
About NoMA (Norwegian Medicines Agency)

- ≈ 360 employees
- Agency under the Ministry of Health and Care Services
- Our goal is to ensure:
  - That medical products are safe and effective.
  - That the population has access to medicines regardless of ability to pay.
  - The correct medicinal and economical use of medicines.
  - The use of cost-effective medicines.
  - That medical devices placed on the market and put into service in Norway meet the regulatory requirements.
- Responsible for delivery of the Medicinal Product Dictionary
- Facilitate new digital information services based on international standards to meet clinical needs
- Contribute to standardising information about medicinal products nationally and in Europe through European cooperation
SAFEST project: actors and set-up

► 4 health regions – specialized care
  ▶ The project is financed by the health regions

► Background drivers:
  ▶ Hospitals using different EHRs and other clinical systems.
  ▶ Reduce manual intervention on the medicinal products data to support clinical use

► Goals:
  ▶ Improved data quality through implementation of IDMP: definition of strength, pharmaceutical dose form, packages, route of administration
  ▶ Prescription based on active substance (INN)
  ▶ Data on nutritional products – parenteral medicinal products and enteral nutrition drinks
  ▶ Product codes on unit level to support Closed-loop medication management

► Close collaboration with hospitals-/clinician representatives

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299
SAFEST technical solution

NoMA's legacy medicinal products database - on premise

Data transfer → Quality improvement → Distribution → FHIR API

SAFEST

EHR systems

Pharmacy systems

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
SAFEST-project: status

► First delivery (Q4 2022):
  ▶ Medicinal products, Package and product codes on every package level in FHIR format
  ▶ GUI for management of terms for pharmaceutical dose form, combined term and more

► Next delivery under testing: GUI for management of terms for substance (delivery Q3 2023)

► Analysis and design: Nutrition, Administrable products, Manufactured Item and Ingredient with strength (delivery Q1 2024)
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299.
Pharmaceutical product in FHIR: AdministrableProductDefinition
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299
What are the challenges?

- Problem 1: Authorised pharmaceutical dose form is deficient
- Problem 2: Manufactured dose form is too ambiguous to be used as administrable dose form for prescription
Problem 1: Authorised dose form is deficient

Cefotaxim Navamedic

Authorized pharmaceutical dose form:
**Powder for solution for injection**

Pharmaceutical product
Administrable dose form:
**Injection, solution**

SmPC section 4.2 (Navamedic):

*Intravenous administration (injection or infusion):*
For intermittent I.V. injections, the solution must be injected over a period of 3 to 5 minutes. During post-marketing surveillance, potentially life-threatening arrhythmia has been reported in a very few patients who received rapid intravenous administration of cefotaxime through a central venous catheter.

Cefotaxim MIP

Authorized pharmaceutical dose form:
**Powder for solution for injection/infusion**

Pharmaceutical product
Administrable dose form:
**Injection, solution**

Pharmaceutical product
Administrable dose form:
**Infusion, solution**

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299
Problem 1: Authorised dose form is deficient

► Authorised pharmaceutical dose form is used to create pharmaceutical products
► Preferred dose form for prescribing to patients
  ▶ If the authorised pharmaceutical dose form is deficient, then we do not have the correct pharmaceutical products
  ▶ This is a risk to patient safety
Different measures taken by NoMA

▶ Working group for standardised medicinal products information
  ▶ Team of colleagues from different units within regulatory affairs and better use of medicines
  ▶ Prioritise and address cases where product information is outdated
  ▶ Contact MAH with advise and guidance on how to change and update information according to standards

▶ SAFEST:
  ▶ Technical solution which makes room for changes in the relation from manufactured to administrable dose form
Problem 2: Manufactured dose form is too ambiguous to be used as administrable dose form for prescription

- IDMP is the chosen standard for expressing data on medicinal products
- PhPID is IDMPs mechanism for the grouping of pharmaceutical products
- PhPID – related use cases assigned to Uppsala Monitoring Centre (UMC):
  - Pharmacovigilance
  - Drug shortages
  - Cross-border Prescription
  - Inpatient care
  - Prescription and dispensing within a country

Clinical use cases
Ability to identify Medicinal Products is key

► In general, a PhPID must group all available pharmaceutical products with equal clinical effects across any context (countries, health institutions, systems etc.).

► As a consequence, the clinical use cases require the PhPID, its generating algorithm and its underlying data to have a number of characteristics.

► The following use case in this presentation focuses on one of these characteristics (unambiguous intended site in administrable dose forms)

► Other characteristics are outlined on the last slide and may be the focus in other workshops and/or presentations
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299

Manufactured dose form “Ear-/eye-/nasal drops, solution”

- The clinician must at least provide a concrete Intended site
- The administrable dose forms must define an unambiguous clinical effect and application.
- PhPID generation for clinical use must be based on these unambiguous administrable dose forms
Manufactured dose form “Ear-/eye-/nasal drops, solution”

- E-prescription based on the dose form «Ear-/eye-/nasal drops, solution» would not yield a complete selection of packaged products with equal clinical effect
- Pharmaceutical products with only auricular/only ocular/only nasal use would be excluded
Use case: “IDMP in a droplet”

► Just before leaving for her summer holiday, Gitte notices that both her eyes are swollen and red.
► Afraid she might have to cancel her vacation, she consults with her doctor just before leaving for Copenhagen airport.
► The doctor diagnoses a bacterial infection and prescribes eye drops. Since Gitte already is on her way to the airport, an e-prescription is sent to her holiday destination, Austria.
► Gitte is happy not having to cancel her vacation. Sunglasses will have to do before getting the prescribed medication.
Use case: “IDMP in a droplet”

► Upon arrival in Vienna, Gitte quickly rushes to the next pharmacy to collect her medication.
► The pharmacist retrieves the e-prescription, but does not find any matching product.
► Gitte desperately tries to find a pharmacy having her medication in stock, but to no avail.
► After a few days of wearing sunglasses, Gitte arranges an appointment with a local doctor, and she can finally get her eye drops medication “White Eye” at a local pharmacy.

But why didn’t “White Eye” show up with her first prescription, even though the substance, dose form and strength are seemingly equal?
Behind the scenes: PhPID (Denmark)

► When creating her e-prescription, the doctor in Copenhagen selected
  ▶ The appropriate **substance** (Ciprofloxacin),
  ▶ ”Ear-/eye-/nasal drops, solution” as **administrable dose form** and
  ▶ 0.5 mg/ml as (concentration) **strength**.

► This combination is represented by the PhPID “77777” which -
together with the dosage - is part of the e-prescription sent to Austria
(or a common European e-prescription database).
Behind the scenes: PhPID (Austria)

- In Austria, there is no pharmaceutical product related to the PhPID on the Danish prescription, since the manufacturer of the product marketed in Denmark ("Wide Eye") did not seek market approval in Austria.

- However, a generic version ("White Eye") is available with:
  - The same substance (Ciprofloxacin),
  - "Eye drops, solution" as administrable dose form and
  - The same (concentration) strength (0.5mg/ml).

- Since the dose form is different from the one represented by the PhPID “77777”, the relevant Austrian product could not be found and dispensed in the pharmacy, and Gitte could not receive her medication.
Equal clinical effect, different PhPID levels

**Denmark: “Wide Eye”**
- Substance: Ciprofloxacin
  - ID: 100.000.263
- Adm. Dose Form: Ear-/eye-/nasal drops, solution
  - ID: 100000074001
- Strength: 0.5mg/ml
  - ID: xxxxxxxxxxx

**PhPID level 4 “77777”**

**Austria: “White Eye”**
- Substance: Ciprofloxacin
  - ID: 100.000.263
- Adm. Dose Form: Eye drops, solution
  - ID: 100000073759
- Strength: 0.5mg/ml
  - ID: xxxxxxxxxxx

**PhPID level 4 “55555”**

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
### Solution 1: Split, one PhPID per Intended Site

**Denmark: “Wide Eye”**

<table>
<thead>
<tr>
<th>Substance: Ciprofloxacin</th>
<th>ID 100.000.263</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adm. Dose Form: Ear-/eye-/nasal drops, solution</td>
<td>ID 100000074001</td>
</tr>
<tr>
<td>Strength: 0,5mg/ml</td>
<td>ID xxxxxxxxxxx</td>
</tr>
</tbody>
</table>

- Adm. Dose Form: Ear drops, solution | ID 100000073786 |
  - PhPID level 4 | “66666” |

- Adm. Dose Form: Eye drops, solution | ID 100000073759 |
  - PhPID level 4 | “55555” |

- Adm. Dose Form: Nasal drops, solution | ID 100000073763 |
  - PhPID level 4 | “33333” |

**Austria: “White Eye”**

<table>
<thead>
<tr>
<th>Substance: Ciprofloxacin</th>
<th>ID 100.000.263</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adm. Dose Form: Eye drops, solution</td>
<td>ID 100000073759</td>
</tr>
<tr>
<td>Strength: 0,5mg/ml</td>
<td>ID xxxxxxxxxxx</td>
</tr>
</tbody>
</table>

- Adm. Dose Form: Eye drops, solution | ID 100000073759 |
  - PhPID level 4 | “55555” |
Solution 2: Hybrid

Denmark: “Wide Eye”

- Substance: Ciprofloxacin
  ID 100.000.263
- Adm. Dose Form: Ear drops, solution
  ID 100000073786
- Adm. Dose Form: Eye drops, solution
  ID 100000073759
- Adm. Dose Form: Nasal drops, solution
  ID 100000073763

Austria: “White Eye”

- Substance: Ciprofloxacin
  ID 100.000.263
- Adm. Dose Form: Eye drops, solution
  ID 100000073759

PhPID levels:
- 4 “66666”
- 4 “55555”
- 4 “33333”
- 4 “77777”
Splitting of manufactured dose form

Transition from manufactured- to administrable dose form is not stated in the EU implementation guide

To meet the needs in clinical practice, NoMA has decided to generate multiple pharmaceutical (administrable) products when the manufactured dose form includes multiple characteristics (intended site or administration method).

- Example 1: products with manufactured dose form ear/eye/nasal drops, will generate 3 different pharmaceutical products, one for each use/intended site

- Other examples: products with manufactured dose form solution for injection/infusion, will generate 2 different pharmaceutical products, one for each administration method
**Legemiddelinform**

- **Kode, intern**: 2011
- **Tønnsstatus, intern**: Godkjent SPOR
- **Tønnsstatus, kilde**: Current
- **Kilde, ekstern**: EDQM
- **Tønns ID (ELMS)**: 100000116151
- **Tønnsnavn, norsk**: Øre-/øye-/nosedråper, oppsløsning
- **Tønnsnavn, engelsk**: Ear/eye/nasal drops, solution
- **Human/ Vet**: Human og veterinær bruk
- **Fra dato**: 22.09.2016
- **Kort navn, norsk**: øre/øye/nosedråper, opp
- **Beskrivelse av term, engelsk**: Liquid sterile preparation consisting of a solution intended for use as ear drops, eye drops or nasal drops.

**Referanse til administrerbar legemiddelinform**

- Administrerbar legemiddelform
- Nosedråper, oppløsning
- Øredråper, oppløsning
- Øreddråper, oppløsning
Other aspects for the clinical use cases

- The example shown is also applicable to multiple values in other Dose Form attributes (Administration Method, Transformation and, to a lesser extend, Release Characteristics).

- Strength: Two pharmaceutical products with equal clinical effect must be grouped by the same PhPID, independent of their strength and / or Basis of Strength Substance (BoSS).
NOMA and WHO-UMC are testing the PhPID generation

The Norwegian Medicines Agency is very much aware of its role of interoperability enabler and has initiated in 2019 the SAFEST project which aims at the distribution of interoperable medicinal master data for clinical use.

On March 29 and 30, the SAFEST project arranged a face2face workshop with WHO Uppsala Monitoring Center (UMC) in Oslo about the PhPID generation. NOMA collaboration with with UMC started in June 2022 and 5 virtual meetings had already taken place.

The UMC has an pivotal role in the generation of a global unique Pharmaceutical Product Identifier (PhPID) for medicinal products (Watch this short interview to understand why). The PhPID must be generated based on substance, dose form and strength.
The information presented is derived from the UNICOM Innovation Action, which receives funding from the European Commission Directorate General for Communications Networks, Content and Technology, in the context of the European Horizon 2020 research and innovation programme under grant agreement No 875299 - support which is gratefully acknowledged.

Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use which might be made of the information presented. The views expressed are solely those of the author(s) and do not necessarily reflect those of the European Commission or any other organisation.

We are most grateful to colleagues at the participating organisations as well as external experts who contribute and critically review project work.
Thank you!